The latest update to official guidelines issued by the U.S. Department of Health and Human Services on the treatment and care of people living with HIV occurred within the pediatric HIV prevention guidelines on April 8.
A recent study finds viral suppression rates and CD4+ cell counts were significantly lower among people experiencing homelessness.
The results: 79% of enrolled participants restarted their antiretroviral therapy within a week of enrolling, and 55% were virally suppressed after six months.
The worst fears about HIV and COVID-19 don’t appear to have materialized, but concerns persist, particularly in cases where HIV treatment efficacy is suboptimal or comorbidities are present.
Tonia Poteat, Ph.D., PA-C, M.P.H., and Marlon M. Bailey, Ph.D., dive into the important takeaways of a major new report on sexual and gender diverse populations in the U.S.
W. David Hardy, M.D., discusses the takeaway messages for HIV care providers after a recent research paper found that a third of all people living with HIV reported never discussing U=U with their provider.
Immediate HIV Treatment Initiation With Integrase Inhibitors Leads to Large Drop in Secondary HIV Transmission Among MSM
Integrase inhibitors are known to be potent first-line therapy options. Recent research suggests their benefits extend to onward HIV prevention as well.
As CATIE reports, a Canadian study found that people living with HIV were more likely to be lonely than the average person—and that loneliness grew more common the younger a person with HIV was.
Recent studies examine the role anal sex is playing in HIV rates and anal cancer among women.
Long-Acting Injectable HIV Meds Just as Good as Daily Pill for Newly Diagnosed and Those Already Undetectable
Questions still remain as to when FDA will approve, and how it will be implemented.
Reducing the time between contracting HIV and being diagnosed and starting treatment is key to ending the epidemic, this study finds.